Logo

AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

Share this

AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

Shots:

  • The approval is based on P-III SOLO-1 study result assessing Lynparza (300mg- bid) as a maintenance monothx. vs PBO in 391 patients in ratio (2:1) with BRCA-mutated advanced ovarian cancer following 1L platinum-based CT
  • The P-III SOLO results demonstrated that 60% of patients showed disease-free progression after three yrs. of treatment and only 27% in patients receiving placebo
  • Lynparza is a PARP inhibitor- act by blocking DNA damage response (DDR) in cells/tumors and has received approval in 60+ countries including the US- EU as 1L maintenance treatment for BRCAm advanced ovarian cancer and in 40+ countries for germline BRCAm HER2-negative metastatic breast cancer

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions